Clinical Trial Update: Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL [Phase 3]

View source ↗

Summary

Phase 3 open-label trial comparing ibrutinib to chlorambucil in patients 65 years or older with treatment-naive chronic lymphocytic leukemia or small lymphocyti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2016-05-04